Why Is ROIVANT SCIENCES LTD (ROIV) Stock Up Today?
By the Top Tier Newswire AI Desk · October 21, 2026 at 9:44 AM ET · reviewed against 9 wire stories
ROIVANT SCIENCES LTD (ROIV) is up +5.24% in the latest session. Our newswire has captured 9 stories on ROIV across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Roivant Sciences (ROIV) shares rose 5.24% to $36.75 on Tuesday. The primary driver was the announcement of positive Phase 3 trial results for brepocitinib, an FDA-approved therapy known as Lisraya, in the treatment of non-infectious uveitis.
What Happened
Roivant and its subsidiary Priovant Therapeutics reported that the CLARITY-1 and CLARITY-2 trials met their primary endpoints. The company stated that brepocitinib achieved all key secondary endpoints in these late-stage studies for the eye disorder. Roivant filed a Form 8-K with the SEC on October 21, 2026, disclosing the Regulation FD material. The company plans to submit a supplemental New Drug Application in the first half of 2027. Additionally, Roivant announced it will report financial results for the second quarter ended September 30, 2026, on a live call at 8:00 a.m. ET on November 9, 2026. An investor day is also scheduled for December 9, 2026.
What The Data Shows
The stock opened at $35.44, a 1.5% gap from the prior close of $34.92. It reached a session high of $38.56 at 9:25 a.m. ET before settling near $36.58. Volume stood at 2.7 million shares, which is 0.4 times the three-month daily average. The company has a market capitalization of $25.1 billion and remains unprofitable with a trailing twelve-month EPS of $0.49. Revenue declined 67.6% over the same period. The stock has a beta of 1.10 and trades within a 52-week range of $17.28 to $42.50. Over the last 8 sessions, the stock moved 1.4% from $34.44 to $34.92. Recent insider activity includes nine sales totaling $59.8 million over the last 90 days, with no buys recorded. The most recent Form 4 filings involved director Melissa B. Epperly and Eric Venker, President of Immunovant.
What To Watch
Investors will focus on the November 9, 2026, earnings call for the second quarter fiscal 2026 results. The company will also provide a business update on that date, with further details expected at the December 9 investor day.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ROIV · today's session (5-min) · +5.44% vs prior close · updated 4:16 PM ETAI sentiment, last 36h · averaged over 9 stories · 65/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
6h agoSeeking AlphaBULLISH 74Product/PR
Roivant to seek label expansion for Lisraya in uveitis after late-stage trial win
Roivant Sciences (ROIV) stock jumps as FDA-approved therapy Lisraya hits late-stage trial wins in an eye disorder called non-infectious uveitis. Read more here.
7h agoInvesting.com MarketsBULLISH 74Product/PR
Roivant Sciences stock surges on positive uveitis trial data
Roivant Sciences stock surges on positive uveitis trial data
8h agoMarketWatchBULLISH 67Product/PR
Roivant Shares Gain on Positive Study Results for Non-Infectious Uveitis Treatment
8h agoMarketChameleonNEUTRAL 52General
Roivant (ROIV) sets Nov. 9 results call and Dec. 9 investor day, putting near-term focus on updates for LISRAYA, IMVT-1402, and mosliciguat
October 21, 2026
Roivant (ROIV) said it will report financial results for the second quarter ended Sept. 30, 2026 and provide a business update on a live call and webcast at 8:00 a.m. ET on Nov. 9, 2026. The company also set an investor day for Dec. 9, 2026, with both events hosted via online registration and materials posted under its “Events & Presentations” page.
8h agoThe FlyBULLISH 74Product/PR
Roivant, Priovant report CLARITY-1 and CLARITY-2 trials meet primary endpoint
8h agoTipRanksBULLISH 74Product/PR
Roivant reports strong Phase 3 data in uveitis
Roivant Sciences ( ($ROIV) ) has issued an update. On October 21, 2026, Roivant and its subsidiary Priovant Therapeutics reported positive Phase 3 results from the ...
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
BASEL, Switzerland and LONDON and NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 9, 2026, to report its financial results...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →